États-Unis · Bourse & Finance · Yahoo Finance

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Publié par Yahoo Finance · États-Unis il y a 1 j

Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

À lire aussi

ByteDance's short-drama app is turning into China's latest obsession

Collective Metals announces $515K non-brokered private placement

Oil Prices Head for Weekly Gain as Hormuz Attacks Rattle Markets

Even Benchmark thinks AI is eroding the venture pact against backing rivals

Balaji’s ‘Singapore of social media’ begins with a wave of bans

Fed's Warsh withholds Fed rate signal, praises recent global tightening with 'no free riders'

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Partager

À lire aussi

ByteDance's short-drama app is turning into China's latest obsession

Collective Metals announces $515K non-brokered private placement

Oil Prices Head for Weekly Gain as Hormuz Attacks Rattle Markets

Even Benchmark thinks AI is eroding the venture pact against backing rivals

Balaji’s ‘Singapore of social media’ begins with a wave of bans

Fed's Warsh withholds Fed rate signal, praises recent global tightening with 'no free riders'